<html>
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
  </head>
  <body>
    <p>Is that the talking point your Big Pharma owned summary journal
      provides you when hard irrefutable evidence is presented that
      natural immunity is better than the covid19 quasi vaccine?  Art<br>
    </p>
    <div class="moz-cite-prefix">On 10/16/21 1:18 p.m., 2docp 2docp
      wrote:<br>
    </div>
    <blockquote type="cite"
cite="mid:625860927.1016499.1634415522279.JavaMail.open-xchange@torgui01">
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <p>Here are just a few infectious diseases that we, thank God, no
        longer rely on "natural immunity":  Small pox, polio,
        diphtheria, pertussis, measles, mumps, rubella, chicken pox,
        yellow fever, tetanus, typhoid, typhus, meningococcus, H.
        influenza.  Paul.</p>
      <blockquote type="cite"> ---------- Original Message ---------- <br>
        From: Arthur Blomme via craic
        <a class="moz-txt-link-rfc2396E" href="mailto:craic@lists.integralshift.ca"><craic@lists.integralshift.ca></a> <br>
        Date: October 16, 2021 at 4:02 PM <br>
        <br>
        <p><span id="bcr_rptStory_cslStory_4">Hi all</span></p>
        <p><span id="bcr_rptStory_cslStory_4">The question I keep asking
            myself is how can you believe anything the CBC says if they
            are so biased in their presentation of Covid19 science. <br>
          </span></p>
        <p><span id="bcr_rptStory_cslStory_4">For the past several
            months the CBC has demonstrated collusion with big Pharma by
            censoring information that does not support the need for
            vaccine mandates. While natural immunity has been considered
            the consequence of surviving all infectious diseases to this
            point, in Canada this logic is denied and not given due
            consideration by Big Pharma, the CBC and most other
            mainstream media sources. In Canada, if you survive the
            disease and acquire natural immunity you will still be
            mandated to get both jabs to save your job. </span><span
            id="bcr_rptStory_cslStory_4"><br>
          </span></p>
        <p><span id="bcr_rptStory_cslStory_4">The general belief seems
            to be that surviving Covid does not give you immunity;
            despite a plethora of scientific studies from reputable
            journals demonstrating the superiority of natural immunity.
            As I have said repeatedly, the only data presented in the
            media is data that support the thesis that vaccines are our
            only salvation from this horrible disease. No nuances
            allowed. This policy is extremely prejudicial to the
            survivors of Covid19. </span><span
            id="bcr_rptStory_cslStory_4"><span
              id="bcr_rptStory_cslStory_4">In addition to having the
              best protection available, those with natural immunity
              also face higher stakes when taking the COVID shot, as
              their preexisting immunity makes them more prone to side
              effects</span>. </span> <a id="lnkReference"
            target="_blank"
            href="https://www.mdpi.com/2075-1729/11/3/249/htm"
            moz-do-not-send="true">Life 2021; 11(3): 249, Discussion</a></p>
        <p><span id="bcr_rptStory_cslStory_4"><span
              id="bcr_FormattedBody">Moreover, the dogmatic ‘get
              vaccinated’ position constitutes a lack of honesty about
              the data . The policy bias in favor of vaccines ignores
              many other facts as well, such as the relative risks of
              vaccines, especially for the young.</span></span></p>
        <p><span id="bcr_rptStory_cslStory_4"><span
              id="bcr_FormattedBody"><em>Below is a list of some of the
                studies that indicate the comparative effectiveness of
                natural immunity over covid19 vaccines: <br>
              </em></span></span></p>
        <blockquote> An Israeli study <sup style="font-size: 10px;"><span
              id="edn4">4</span></sup> that included 700,000 people,
          posted August 25, 2021, on the preprint server medRxiv, found
          those with prior SARS-CoV-2 infections were 27 times less
          likely to develop symptomatic infection for a second time,
          compared to those who were vaccinated.
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref4"><span
                    id="lblReferenceNo">4</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1"
                moz-do-not-send="true">medRxiv August 25, 2021</a></li>
          </ul>
          <div class="MidProductAd">   <br>
          </div>
          <p>A June 11, 2021, Public Health England report<sup
              style="font-size: 10px;"><span id="edn5">5</span></sup>
            also showed that as a hospital patient, you are six times
            more likely to die of the COVID Delta variant if you are
            fully vaccinated, than if you are not vaccinated at all.</p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref5"><span
                    id="lblReferenceNo">5</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf"
                moz-do-not-send="true">Public Health England Briefing 15
                June 3, 2021</a></li>
          </ul>
          <p>October 4, 2021, Project Veritas released a video<sup
              style="font-size: 10px;"><span id="edn6">6</span></sup>
            (below) in which Pfizer scientist Nick Karl states, “When
            somebody is naturally immune ... they probably have more
            antibodies against the virus,” correctly explaining that
            “When you actually get the virus, you’re going to start
            producing antibodies against multiple pieces of the virus
            ... So, your antibodies are probably better at that point
            than the [COVID] vaccination.” <br>
          </p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref6"><span
                    id="lblReferenceNo">6</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://www.projectveritas.com/news/pfizer-scientist-your-antibodies-are-probably-better-than-the-vaccination/"
                moz-do-not-send="true">Project Veritas October 4, 2021</a></li>
          </ul>
          <p> <br>
          </p>
          <p>Yet another senior associate scientist at Pfizer, Chris
            Croce, is caught saying that “You’re protected for longer”
            if you have natural COVID antibodies compared to the COVID
            vaccine. Croce adds that he works “for an evil corporation”
            that is “run on COVID money.</p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref7"><span
                    id="lblReferenceNo">7</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://www.reddit.com/r/LockdownSkepticism/comments/oy84pe/covid19_and_immunity/"
                moz-do-not-send="true">Reddit COVID-19 and Immunity</a></li>
          </ul>
          <p>”Science Immunology October 2020 found that “RBD-targeted
            antibodies are <span id="bcr_FormattedBody">excellent
              markers of previous and recent infection, that
              differential isotype measurements can help distinguish
              between recent and older infections, and that IgG
              responses persist over the rst few months after infection
              and are highly correlated with neutralizing antibodies.”</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref8"><span
                    id="lblReferenceNo">8</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://immunology.sciencemag.org/content/5/52/eabe0367"
                moz-do-not-send="true">Science Immunology October 8,
                2020; 5(52): eabe0367</a></li>
          </ul>
          <p><span id="bcr_FormattedBody">The BMJ January 2021<sup
                style="font-size: 10px;"><span id="edn9">9</span></sup>
              concluded that “Of 11, 000 health care workers who had
              proved evidence of infection during the first wave of the
              pandemic in the U.K. between March and April 2020, none
              had symptomatic reinfection in the second wave of the
              virus between October and November 2020.”</span></p>
          <br>
          <span id="bcr_FormattedBody"></span>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref9"><span
                    id="lblReferenceNo">9</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://www.bmj.com/content/372/bmj.n99"
                moz-do-not-send="true">BMJ 2021;372:n99</a></li>
          </ul>
          <p> <br>
          </p>
          <p>Science February 2021<sup style="font-size: 10px;"><span
                id="edn10">10</span></sup> reported that “Substantial
            immune memory is generated after COVID-19, involving all
            four major types of immune memory [antibodies, memory B
            cells, memory CD8+ T cells, and memory CD4+ T cells]. About
            95% of subjects retained immune memory at ~6 months after
            infection.<br>
          </p>
          <p> <br>
          </p>
          <p><span id="bcr_FormattedBody">Circulating antibody titters
              were not predictive of T cell memory. Thus, simple
              seriological tests for SARS-CoV-2 antibodies do not
              reflect the richness and durability of immune memory to
              SARS-CoV-2. A 2,800-person study found no symptomatic
              reinfections over a ~118-day window, and a 1,246-person
              study observed no symptomatic reinfections over 6
              months.”symptomatic reinfections over 6 months.”</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref10"><span
                    id="lblReferenceNo">10</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://science.sciencemag.org/content/371/6529/eabf4063"
                moz-do-not-send="true">Science February 5, 2021;
                371(6529): eabf4</a><span id="bcr_FormattedBody"></span></li>
          </ul>
          <span id="bcr_FormattedBody">A February 2021 study posted on
            the prepublication server medRxiv<sup style="font-size:
              10px;"><span id="edn11">11</span></sup> concluded that
            “Natural infection appears to elicit strong protection
            against reinfection with an efficacy ~95% for at least seven
            months.”</span> <br>
          <ul>
            <li><a id="lnkReference" target="_blank"
                href="https://www.medrxiv.org/content/10.1101/2021.01.15.21249731v2"
                moz-do-not-send="true">medrxiv February 8, 2021 DOI:
                10.1101/2021.01.15.21249731</a></li>
          </ul>
          <p><span id="bcr_FormattedBody"></span><span
              id="bcr_FormattedBody">An April 2021 study posted on
              medRxiv<sup style="font-size: 10px;"><span id="edn12">12</span></sup>
              reported “the overall estimated level of protection from
              prior SARS-CoV-2 infection for documented infection is
              94.8%; hospitalization 94.1%; and severe illness 96·4%.
              Our results question the need to vaccinate
              previously-infected individuals.”</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref12"><span
                    id="lblReferenceNo">12</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1.full.pdf"
                moz-do-not-send="true">medRxiv April 24, 2021 (PDF)</a></li>
          </ul>
          <p><span id="bcr_FormattedBody"></span><span
              id="bcr_FormattedBody">Another April 2021 study posted on
              the preprint server BioRxiv<sup style="font-size: 10px;"><span
                  id="edn13">13</span></sup> concluded that “following a
              typical case of mild COVID-19, SARS-CoV-2-specific CD8+ T
              cells not only persist but continuously differentiate in a
              coordinated fashion well into convalescence, into a state
              characteristic of long-lived, self-renewing memory.”</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref13"><span
                    id="lblReferenceNo">13</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://www.biorxiv.org/content/10.1101/2021.04.28.441880v1"
                moz-do-not-send="true">BioRxiv April 29, 2021 DOI:
                10.1101/2021.04.28.441880</a></li>
          </ul>
          <p><br>
            <span id="bcr_FormattedBody"></span><span
              id="bcr_FormattedBody">A May 2020 report in the journal
              Immunity<sup style="font-size: 10px;"><span id="edn14">14</span></sup>
              confirmed that SARS-CoV-2-specific neutralizing antibodies
              are detected in COVID-19 convalescent subjects, as well as
              cellular immune responses. Here, they found that
              neutralizing antibody titers do correlate with the number
              of virus-specific T cells.</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref14"><span
                    id="lblReferenceNo">14</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://www.cell.com/immunity/fulltext/S1074-7613(20)30181-3?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1074761320301813%3Fshowall%3Dtrue"
                moz-do-not-send="true">Immunity June 16, 2020; 52(6):
                971-977.E3</a></li>
          </ul>
          <p><br>
            <span id="bcr_FormattedBody"><span id="bcr_FormattedBody">A
                May 2021 Nature article<sup style="font-size: 10px;"><span
                    id="edn15">15</span></sup> found SARS-CoV-2
                infection induces long-lived bone marrow plasma cells,
                which are a crucial source of protective antibodies.
                Even after mild infection, anti-SARS-CoV-2 spike protein
                antibodies were detectable beyond 11 months’
                post-infection.</span></span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref15"><span
                    id="lblReferenceNo">15</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://www.nature.com/articles/s41586-021-03647-4"
                moz-do-not-send="true">Nature 2021; 595: 421-425</a></li>
          </ul>
          <p><span id="bcr_FormattedBody">A May 2021 study in E Clinical
              Medicine<sup style="font-size: 10px;"><span id="edn16">16</span></sup>
              found “antibody detection is possible for almost a year
              post-natural infection of COVID-19.” According to the
              authors, “Based on current evidence, we hypothesize that
              antibodies to both S and N-proteins after natural
              infection may persist for longer than previously thought,
              thereby providing evidence of sustainability that may
              influence post-pandemic planning.”</span><br>
          </p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref16"><span
                    id="lblReferenceNo">16</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://www.thelancet.com/action/showPdf?pii=S2589-5370(21)00182-6"
                moz-do-not-send="true">E Clinical Medicine 2021; 36:
                100902 (PDF)</a></li>
          </ul>
          <p> <br>
          </p>
          <p><span id="bcr_FormattedBody">Cure-Hub data<sup
                style="font-size: 10px;"><span id="edn17">17</span></sup>
              confirm that while COVID shots can generate higher
              antibody levels than natural infection, this does not mean
              vaccine-induced immunity is more protective. Importantly,
              natural immunity confers much wider protection as your
              body recognizes all five proteins of the virus and not
              just one. With the COVID shot, your body only recognizes
              one of these proteins, the spike protein.</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref17"><span
                    id="lblReferenceNo">17</span></span></sup> <a
                id="lnkReference" target="_blank"
href="https://www.cure-hub.com/post/covid-19-natural-infection-vs-vaccine-immunity"
                moz-do-not-send="true">Cure-hub June 11, 2021</a></li>
          </ul>
          <p> <br>
          </p>
          <p>A June 2021 Nature article<sup style="font-size: 10px;"><span
                id="edn18">18</span></sup> points out that “Wang et al.
            show that, between 6 and 12 months after infection, the
            concentration of neutralizing antibodies remains unchanged.
            That the acute immune reaction extends even beyond six
            months is suggested by the authors’ analysis of
            SARS-CoV-2-specific memory B cells in the blood of the
            convalescent individuals over the course of the year.</p>
          <p>These memory B cells continuously enhance the reactivity of
            their SARS-CoV-2-specific antibodies through a process known
            as somatic hypermutation. The good news is that the evidence
            thus far predicts that infection with SARS-CoV-2 induces
            long-term immunity in most individuals.”</p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref18"><span
                    id="lblReferenceNo">18</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://www.nature.com/articles/d41586-021-01557-z"
                moz-do-not-send="true">Nature June 14, 2021</a></li>
          </ul>
          <p><span id="bcr_FormattedBody">Another June Nature paper<sup
                style="font-size: 10px;"><span id="edn19">19</span></sup>
              concluded that “In the absence of vaccination antibody
              reactivity [to the receptor binding domain (RBD) of
              SARS-CoV-2], neutralizing activity and the number of
              RBD-specific memory B cells remain relatively stable from
              6 to 12 months after infection.” According to the authors,
              the data suggest “immunity in convalescent individuals
              will be very long lasting.”</span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref19"><span
                    id="lblReferenceNo">19</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://pubmed.ncbi.nlm.nih.gov/34126625/"
                moz-do-not-send="true">Nature July 2021; 595(7867):
                426-431</a></li>
          </ul>
          <p><span id="bcr_FormattedBody"><span id="bcr_FormattedBody">A
                September 2021 paper<sup style="font-size: 10px;"><span
                    id="edn20">20</span></sup> in the European Journal
                of Immunology assessed the persistence of serum
                antibodies following wild-type SARS-CoV-2 infection at 8
                and 13 months after diagnosis in 367 patients. At 13
                months, neutralizing antibodies against the wild-type
                virus persisted in 89% of cases, and SARS-CoV-2 spike
                immunoglobulin G (S-IgG) persisted in 97% of cases.</span></span></p>
          <ul id="footnote-references2">
            <li><sup style="font-size: 10px;"><span id="ednref20"><span
                    id="lblReferenceNo">20</span></span></sup> <a
                id="lnkReference" target="_blank"
                href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202149535"
                moz-do-not-send="true">European Journal of Immunology
                September 24, 2021 DOI: 10.1002/eji.202149535</a></li>
          </ul>
        </blockquote>
        <p> <br>
        </p>
        <p><br>
        </p>
        <p><br>
        </p>
        <p>Peace <br>
        </p>
        <p>Art Blomme</p>
        <p><br>
          <span id="bcr_FormattedBody"></span></p>
      </blockquote>
      <p><br>
         </p>
      <blockquote type="cite">
        _______________________________________________ <br>
        craic mailing list <br>
        To send message: <a class="moz-txt-link-abbreviated" href="mailto:craic@integralshift.ca">craic@integralshift.ca</a> <br>
        To manage Subscription:
        <a class="moz-txt-link-freetext" href="http://lists.integralshift.ca/listinfo.cgi/craic-integralshift.ca">http://lists.integralshift.ca/listinfo.cgi/craic-integralshift.ca</a>
        <br>
        To Unsubscribe send email to: <a class="moz-txt-link-abbreviated" href="mailto:craic-unsubscribe@integralshift.ca">craic-unsubscribe@integralshift.ca</a>
        <br>
        To Subscribe send email to: <a class="moz-txt-link-abbreviated" href="mailto:craic-subscribe@integralshift.ca">craic-subscribe@integralshift.ca</a> </blockquote>
      <p><br>
         </p>
    </blockquote>
  </body>
</html>